Fifth Third Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Fifth Third Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$575K	Sell	3,414 -149	-4%	-$22.1K	0.02%	447
2026 Q1	$469K	Buy	3,563 +430	+14%	+$57.1K	0.02%	445
2025 Q4	$444K	Hold	3,133	–	–	0.02%	430
2025 Q3	$440K	Buy	3,133 +9	+0.3%	+$1.22K	0.02%	423
2025 Q2	$393K	Sell	3,124 -67	-2%	-$7.68K	0.02%	434
2025 Q1	$353K	Buy	3,191 +10	+0.3%	+$1.27K	0.02%	435
2024 Q4	$434K	Hold	3,181	–	–	0.02%	371
2024 Q3	$367K	Buy	3,181 +24	+0.8%	+$3.29K	0.02%	392
2024 Q2	$435K	Buy	+3,157	New	+$433K	0.03%	301

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Fifth Third Wealth Advisors's NBIX Position: Q2 2026 in Review

Fifth Third Wealth Advisors reduced its Neurocrine Biosciences (NBIX) stake by 4.2% in Q2 2026, selling an estimated $22.1K and leaving 3,414 shares worth $575K. The position accounts for 0.02% of the portfolio, ranked #447.

Fifth Third Wealth Advisors first reported a position in NBIX in Q2 2024 and has held it in 9 quarters since. 116 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Fifth Third Wealth Advisors held 3,414 shares of Neurocrine Biosciences worth $575K as of Q2 2026.
Fifth Third Wealth Advisors sold 149 Neurocrine Biosciences shares in Q2 2026, an estimated $22.1K.
Neurocrine Biosciences made up 0.02% of Fifth Third Wealth Advisors's portfolio in Q2 2026, its #447 holding.
Fifth Third Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 9 quarters since.
116 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fifth Third Wealth Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.